Patents Assigned to LIHPAO LIFE SCIENCE CORP.
  • Method for evaluating the efficacy of an EGFR-TKI treatment
    Patent number: 10829822
    Abstract: The present invention provides a method for evaluating the efficacy of an EGFR-TKI treatment to a subject, comprising identifying the V384D mutation in said subject. By identifying said mutation, the efficacy of the EGFR-TKI treatment and the progression-free survival of said subject after treatment can be estimated.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: November 10, 2020
    Assignee: LIHPAO LIFE SCIENCE CORP.
    Inventors: Teh-Ying Chou, Chun-Ming Tsai
  • Kit for cancer detection
    Patent number: 10378067
    Abstract: The present invention provides a primer set and a kit containing same for analyzing a sequence of an MLH1 DNA, an MLH1 mRNA, and/or a cDNA sequence derived from said MLH1 mRNA of a subject to identify a V384 alteration of an MLH1 gene encoded protein.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: August 13, 2019
    Assignee: LIHPAO LIFE SCIENCE CORP.
    Inventors: Chih-Hao Chen, Meng-Ju Lee, Chia-Lin Wu, Yu-Wei Liu
  • METHOD FOR EVALUATING THE EFFICACY OF AN EGFR-TKI TREATMENT
    Publication number: 20190010561
    Abstract: The present invention provides a method for evaluating the efficacy of an EGFR-TKI treatment to a subject, comprising identifying the V384D mutation in said subject. By identifying said mutation, the efficacy of the EGFR-TKI treatment and the progression-free survival of said subject after treatment can be estimated.
    Type: Application
    Filed: September 21, 2018
    Publication date: January 10, 2019
    Applicant: LIHPAO LIFE SCIENCE CORP.
    Inventors: Teh-Ying CHOU, Chun-Ming TSAI
  • Method for evaluating the efficacy of an EGFR-TKI treatment
    Patent number: 10106856
    Abstract: The present invention provides a method for evaluating the efficacy of an EGFR-TKI treatment to a subject, comprising identifying the V384D mutation in said subject. By identifying said mutation, the efficacy of the EGFR-TKI treatment and the progression-free survival of said subject after treatment can be estimated.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: October 23, 2018
    Assignee: LIHPAO LIFE SCIENCE CORP.
    Inventors: Teh-Ying Chou, Chun-Ming Tsai
  • Kit for Cancer Detection
    Publication number: 20170292164
    Abstract: The present invention provides a primer set and a kit containing same for analyzing a sequence of an MLH1 DNA, an MLH1 mRNA, and/or a cDNA sequence derived from said MLH1 mRNA of a subject to identify a V384 alteration of an MLH1 gene encoded protein.
    Type: Application
    Filed: September 16, 2015
    Publication date: October 12, 2017
    Applicant: Lihpao Life Science Corp.
    Inventors: CHIH-HAO CHEN, MENG-JU LEE, CHIA-LIN WU, YU-WEI LIU
  • METHOD FOR EVALUATING THE EFFICACY OF AN EGFR-TKI TREATMENT
    Publication number: 20150252435
    Abstract: The present invention provides a method for evaluating the efficacy of an EGFR-TKI treatment to an object, comprising identifying the V384D mutation in said object. By identifying said mutation, the efficacy of the EGFR-TKI treatment and the progression-free survival of said object after treatment can be estimated.
    Type: Application
    Filed: March 10, 2015
    Publication date: September 10, 2015
    Applicant: LIHPAO LIFE SCIENCE CORP.
    Inventors: Teh-Ying CHOU, Chun-Ming TSAI